SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (7618)10/31/1998 9:40:00 PM
From: Bluegreen  Read Replies (2) | Respond to of 17367
 
Cacaito, so you don't think BPI added to effectiveness or rapidity of bactericidal action of conventional antibiotics administered in the setting of the Phase II Meningo.? And if so why not?



To: Cacaito who wrote (7618)11/1/1998 8:57:00 AM
From: Robert K.  Respond to of 17367
 
And all of those possible factors in meningococcemia are all seemingly inter-related in some way shape or form.
Dead bacteria releases endotoxin which activates cd14 which activates cytokines which causes DIC, which ALL comes back to bpi dude. So where is the point of intervention needed? Which is the effective cause of mortality? What can bpi bring to the table?
Dont you just love it when I am on a roll.............VBG
All IMO



To: Cacaito who wrote (7618)11/1/1998 8:15:00 PM
From: Robert S.  Respond to of 17367
 
Cacaito, as is often the case, you have made some valid points but there are some statements from your last post that warrant comment:

Robert S, it is a review, not an original work, the bottom of the reference specify it.

While it may be a review and not an original work, the fact that it was published in a peer-reviewed medical journal suggests that at least some members of the medical community agree with the conclusions presented, and attest to the scientific accuracy and validity of the study. Granted, peer-review is not foolproof, but it does filter out those studies lacking in any of said criteria.

Holzheimer refers to certain recent works against the evidence that suppressing
endotoxins is not worth it, well that probably is referring to other failures we have
review before (E5, antiTNF, Cento drug....),
What does that has to do with BPI, did he included BPI "failures" as evidence, Not.
I do not have the full printed version, I do not know what does he refer to.


The review article was published in 1998 and I have to believe that a researcher in this field would be cognizant of BPI.

Your reference is a very good review. This is very important to sit down and learn.
But, one will not get a new development from it.

It is the difference between reviewing the work of Kenneth Starr or actually doing
the investigation. Everybody has an opinion about it, but He did the work.


A peer-reviewed scientific review does have attributes (e.g., 20-20 hindsight, comparison to similar studies, a greater degree of objectivity) that an original research project lacks and, as you said, one can learn from it. Similarly, the fact that a published article pertains to original research, does not guarantee that the research adds to our collective knowledge. If we accept, as scientifically correct, your critique of the Lutsar study, then this illustrates that original research may very well lack some of the benefits of published reviews. In fact, was not your critique of the Lutsar study itself a review? And, did we not learn perhaps more from your comments and opinions than those who performed the actual investigation?



To: Cacaito who wrote (7618)11/2/1998 10:04:00 PM
From: Robert S.  Read Replies (1) | Respond to of 17367
 
Cacaito, I value your opinions and would like to hear your comments on the contradictory evidence pertaining to endotoxins and septic shock. The following journal abstract review is a case in point:

Infect Agents Dis 1993 Feb;2(1):35-43

Endotoxin as a therapeutic target in septic shock.

Corriveau CC, Danner RL

Critical Care Department, Children's National Medical Center, Washington, D.C.

Endotoxin initiates a broad inflammatory response in mammals that has many similarities to de novo septic shock in patients. The presumed role of endotoxin
in septic shock has led to the investigation of antiendotoxin therapies for the treatment of this syndrome. However, a causative role for endotoxin in human
septic shock has not been established. Recent information about the biochemistry of endotoxin, mechanisms of endotoxin-induced cell activation, and the
pathogenesis of septic shock has provided insights useful to the development of new antiendotoxin agents, but also has raised concerns about the suitability of
endotoxin as a therapeutic target.
Definitive proof of the pathogenic importance of endotoxin in human septic shock will depend upon demonstrating that a
putative antiendotoxin therapy has clinical efficacy.

Publication Types:

Review
Review, tutorial

PMID: 8162352, UI: 94214877